<DOC>
	<DOCNO>NCT02606461</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled , Phase 2-3 study patient diagnose advanced unresectable dedifferentiate liposarcoma . Approximately 245 total patient randomize study treatment ( selinexor placebo ) .</brief_summary>
	<brief_title>Selinexor Advanced Liposarcoma</brief_title>
	<detailed_description>In Phase 2 portion study , approximately 50 patient randomize selinexor ( 60 mg ) placebo 1:1 allocation ratio . In Phase 3 portion study , approximately 195 patient randomize selinexor ( 60 mg ) placebo 2:1 allocation ratio . Patients progress blind portion study unblinded receiving : - placebo , may cross open-label selinexor ( 60mg twice weekly ) - selinexor , withdrawn treatment follow survival Study treatment give twice weekly Day 1 Day 3 Weeks 1-6 six-week ( 42 day ) cycle disease progression intolerability . Treatment continue one follow occurs : - Disease progression , define WHO criteria - Clinical progression , determine treat physician - Unacceptable AEs failure tolerate study treatment - Patient withdrawal - Patient discontinuation due non-compliance</detailed_description>
	<mesh_term>Liposarcoma</mesh_term>
	<criteria>1 . Patients ≥12 year age 2 . Body surface area ( BSA ) ≥ 1.2 m2 3 . Histologic evidence DDLS time prior randomization AND current evidence DDLS require treatment 4 . Must measurable disease bidimensional WHO Response Criteria 5 . Radiologic evidence disease progression within 6 month prior randomization . If patient receive intervening therapy document disease progression , disease progression must document completion intervene therapy 6 . Must least one ( 1 ) prior line systemic therapy liposarcoma ( maximum number ) 7 . If patient receive previous systemic therapy , last dose must ≥ 21 day prior randomization ( ≥ 5 halflives drug whichever short ) clinically significant therapy relate toxicity resolve less equal Grade 1 1 . Patients pure WDLS , myxoid/round cell pleomorphic tumor histologic subtypes . 2 . Known active Hepatitis B ( HepB ) , Hepatitis C ( HepC ) human immunodeficiency virus ( HIV ) infection . 3 . Known central nervous system metastasis</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Advanced unresectable dedifferentiate liposarcoma</keyword>
	<keyword>selinexor</keyword>
	<keyword>KCP-330</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>Phase 2 / 3</keyword>
	<keyword>dedifferentiate liposarcoma</keyword>
	<keyword>liposarcoma</keyword>
</DOC>